Navigation Links
Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
Date:2/17/2013

ZURICH, February 18, 2013 /PRNewswire/ --

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia. The new results are from a  recent double-blind, randomized, placebo controlled, parallel group, non-confirmatory, sleep-laboratory study. The study evaluated piromelatine compared to placebo in 120 adult primary insomnia patients ages 18 years and older.

Piromelatine 20/50mg treatment for 4 weeks resulted in statistically significant and clinically meaningful improvements relative to placebo in key  polysomnographic (PSG) parameters including Wake After Sleep Onset (WASO) (p=0.02 for both doses) and in particular WASO for the first 6 hours of sleep (WASO-6h) (p=0.0008 and p=0.04 for the 50 mg and 20 mg groups, respectively). Piromelatine 50 mg also improved Sleep Efficiency (SEF) (p=0.02), Total Sleep Time (TST) (p=0.02), Total Time Awake (TTA) (p=0.01) and time in NREM sleep (p=0.028) indicating beneficial effects on sleep maintenance. Subjective improvements relative to placebo in quality of sleep and total sleep time measured by the Pittsburg Sleep Quality Questionnaire (PSQI) were also observed, confirming the PSG findings. Piromelatine enhanced NREM sleep EEG delta power and significantly reduced beta power (p<0.05). The decrease in EEG beta activity, a marker of cortical arousal, is a physiological surrogate marker of the efficacy of Piromelatine in sleep maintenance. Piromelatine was generally safe and well tolerated, had no detrimental effects on next-day psychomotor performance (as assessed by the Digit Symbol Substitution Test (DSST)) for any dose group and no deleterious effects on sleep structure and architecture.

"Piromelatine demonstrates a good potential for the treatm
'/>"/>

SOURCE Neurim Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014  Decision Resources Group ... (P&R) decision criteria and payer requirements in ... into each country, allow pharma to leverage ... Global market access is extremely complex, with ... requirements and challenges—and a vast variety of ...
(Date:9/23/2014)... 23, 2014 Research and Markets  has announced ... report to their offering. Diabetes is ... globe. Over 382 million people are estimated to be currently ... to 592 million by 2035. With a very high ... and India , an increasing ...
(Date:9/23/2014)... DUBLIN , September 23, 2014 /PRNewswire/ ... ) has announced the addition of the  ...  report to their offering.  ... injectable drug delivery market holds significant potential ... with vials and painful needles to the ...
Breaking Medicine Technology:Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 2Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 3Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 4Glycated Haemoglobin (HbA1c) Testing Market 2Glycated Haemoglobin (HbA1c) Testing Market 3Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5
... February 23 BN,ImmunoTherapeutics, Inc. today provided updated ... vaccine, MVA-BN(R)-HER2, in development as,therapy of metastatic breast ... its primary endpoint with regards to safety and ... immune response was,detected in approximately 70% of evaluated ...
... An international team of,researchers has evaluated ... the knee, and the results have been ... journal "Osteoarthritis and Cartilage".,The researchers followed 376 ... treatments. After six months as well as ...
Cached Medicine Technology:BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 2BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 3New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years 2
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 ... on Manhattan’s Upper West Side that embodies the ... Inhabiting Eden: Christians, Scripture and the Ecological Crisis, ... A. B. Rhodes Professor Emerita of Old Testament ... Bible for ancient wisdom that lends insight into ...
(Date:9/23/2014)... A national report showing the benefits of preventing ... providing Medicaid services was released today by the ... "Why Congress Must Save the Medicaid Primary Care ... Ensure Access to Life-Saving Primary Care Will Expire," ... patients, access to internists and pediatricians (and their ...
(Date:9/23/2014)... 2014 The Sloane Clinic™, a ... and Malaysia providing advanced aesthetic dermatology and cosmetic ... its impressive skin care repertoire. Specially formulated with ... against the evil forces of aging, acne and ... this new addition is revolutionizing the way we ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- The ... million in additional funding in scientific trials to ... and clinical studies. The supplemental monies were ... fields, including basic immunology, cardiovascular physiology, neural circuitry, ... Sept. 23. "This funding strategy demonstrates our ...
(Date:9/23/2014)... Klose, professor of biology and a researcher in UTSA,s ... up with researchers at Ruhr University in Bochum, Germany ... findings were released this week in an article published ... Sciences . , Cholera is an acute infection caused ... with the bacterium Vibrio cholerae . An estimated ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2
... BIRMINGHAM, Ala. Leading high-performance computing engineers and ... University of Alabama at Birmingham (UAB) have called ... group says growing world-wide computer use puts more ... projects that are stored digitally at risk for ...
... lanes could protect more riders, researchers say , WEDNESDAY, Oct. ... and longer hospital stays, with both worsening over the past ... results of a study of biking injuries. , Chest injuries ... last five years, the study authors found. Cyclists themselves appear ...
... , MENLO PARK, Calif., Oct. 14 New Enterprise Associates, ... that Ravi Viswanathan, PhD, has been promoted to General Partner. ... on energy and growth equity information technology investments, as well ... Frank Torti, MD, to Principal. Dr. Torti joined NEA in ...
... ... industry, announced the addition of certain providers of Sistemas Medicos Nacionales, S.A. de C.V. (SIMNSA) ... ... a global health care company in the emerging medical tourism industry, announced the addition of ...
... As the leaves begin to change color and ... today announced the launch of "A BETTER BEDTIME," its 2009-2010 ... campaign is based online at the Official Pajama Program A ... , Pajama Program provides new pajamas and new books to ...
... a third of deaths, study finds, , WEDNESDAY, Oct. 14 (HealthDay ... who share a bed or sofa with a parent, and alcohol ... many of the cases, says a U.K. study. , Researchers analyzed ... between January 2003 and December 2006. Of the deaths, 54 percent ...
Cached Medicine News:Health News:UAB international conference focuses on preventing high-capacity computer data theft 2Health News:As More Cyclists Hit the Road, Serious Injuries Rise 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 3Health News:SIMNSA is added to the Satori Global Network&#8482; in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 2Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 3Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 4Health News:Shared Bed May Raise SIDS Risk 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: